ArticleBMC complementary and alternative medicine2018
Aloe-emodin induces apoptosis in human oral squamous cell carcinoma SCC15 cells.
Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Insights into the computer-aided drug design and discovery based on anthraquinone scaffold for cancer treatment: A systematic review.PloS one · 2024Pooled it
- Phytochemistry, Bioavailability, and Molecular Mechanisms Underlying Multitarget Anticancer Activity ofNutrients · 2026Review
- Nanodelivery Approaches of Phytoactives for Skin Cancers: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Mitigating Risk of Premature Ovarian Insufficiency Using Adjunct Chinese Herbal Medicines: A Nested Patient-Control Study in Female Cancer Patients with Chemotherapy.International journal of women's health · 2025Article
- Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.International journal of molecular sciences · 2024Review
- Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.Cancers · 2024Review
- Mechanism of antibacterial phytoconstituents: an updated review.Archives of microbiology · 2024Review
- Advances in Small Molecular Agents against Oral Cancer.Molecules (Basel, Switzerland) · 2024Review
- Aloe-emodin: Progress in Pharmacological Activity, Safety, and Pharmaceutical Formulation Applications.Mini reviews in medicinal chemistry · 2024Review
- Naturally Isolated Sesquiterpene Lactone and Hydroxyanthraquinone Induce Apoptosis in Oral Squamous Cell Carcinoma Cell Line.Cancers · 2023Article
- The Comparison of the Efficiency of Emodin and Aloe-Emodin in Photodynamic Therapy.International journal of molecular sciences · 2022Article
- Overview of the Biological Activity of Anthraquinons and Flavanoids of the PlantMolecules (Basel, Switzerland) · 2022Review
- Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Advances in Understanding the Role of Aloe Emodin and Targeted Drug Delivery Systems in Cancer.Oxidative medicine and cellular longevity · 2022Review
- Molecular mechanisms and associated cell signalling pathways underlying the anticancer properties of phytochemical compounds fromExperimental and therapeutic medicine · 2021Review
- Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.Drug design, development and therapy · 2021Observational
- Aloe and its Effects on Cancer: A Narrative Literature Review.The East African health research journal · 2021Review
- Network Pharmacology-Based Approach to Investigate the Molecular Targets of Rhubarb for Treating Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Anti-Cancer Effect of 3-Hydroxy-β-Ionone Identified fromMolecules (Basel, Switzerland) · 2020Article
- Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.Investigational new drugs · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOral and pharyngeal cancer is the most common malignant human cancers. Chemotherapy is an effective approach for anti-oral cancer therapy, while the drug tolerance and resistance remain a problem for oral cancer patients. Aloe-emodin, rhein and physcion are classified as anthraquinones, which are the main pharmacodynamic ingredients of Rheum undulatum L.. This study was undertaken to investigate whether aloe-emodin, rhein and physcion show inhibiting growth and inducing apoptosis in oral squamous cell carcinoma SCC15 cells. We found that aloe-emodin show inhibiting growth and inducing apoptosis in oral squamous cell carcinoma SCC15 cells, we also investigated the underlying mechanisms of apoptosis induced by aloe-emodin.
methodsThiazolyl blue tetrazolium bromide (MTT) test was used to detect cell proliferation. Cell apoptosis was detected by flow cytometry. We also used western blot analysis to detect the potential mechanisms of apoptosis.
resultsAloe-emodin, rhein and physcion inhibit the proliferation of SCC15 cells and the order of inhibition level are aloe-emodin > Rhein > Physcion, the half maximal inhibitory concentrations (IC
conclusionsOur results revealed that aloe-emodin treatment could inhibit cell viability of SCC15 cells and the potential mechanism of inhibition might be through the induction of apoptosis by regulation of the expression levels of caspase-9 and caspase-3. This indicates that aloe-emodin may be a good agent for anti-oral cancer drug exploring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.